載入...
Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial
OBJECTIVE: Axitinib is a potent and selective inhibitor of vascular endothelial growth factor receptors 1–3. This analysis compared efficacy and safety of axitinib plus gemcitabine in patients with advanced pancreatic cancer from Japan, North America and the European Union, enrolled in a randomized...
Na minha lista:
| 發表在: | Jpn J Clin Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Oxford University Press
2015
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4412139/ https://ncbi.nlm.nih.gov/pubmed/25647781 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jjco/hyv011 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|